MBIO — MindBio Therapeutics Cashflow Statement
0.000.00%
- CA$3.53m
- CA$7.86m
Annual cashflow statement for MindBio Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -0.477 | -7.51 | -4.29 | -0.407 |
Non-Cash Items | 0 | 1.96 | 2.36 | 0.196 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.477 | 0.823 | -0.289 | -0.173 |
Change in Accounts Receivable | ||||
Change in Payable / Accrued Expenses | ||||
Change in Other Liabilities | ||||
Cash from Operating Activities | 0 | -4.72 | -2.21 | -0.383 |
Other Investing Cash Flow Items | 0 | -0.033 | 0 | — |
Purchase of Investments | ||||
Cash from Investing Activities | 0 | -0.033 | 0 | — |
Financing Cash Flow Items | — | — | — | 0.285 |
Other Financing Cash Flow | ||||
Total Cash Dividends Paid | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 0.48 | 5.59 | 1.04 | 0.272 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 0.48 | 0.835 | -0.996 | -0.18 |